Woodburn.... brings back old days and old lessons.
Thanks, Stan. Good stuff all over the program. Nothing, however, from Brown or Wachter et al. Here's stuff from the links......
PRECLINICAL CARDIOVASCULAR INDICATIONS USING MOTEXAFIN
LUTETIUM
Authors:
K.W. Woodburn
Institutions:
Pharmacyclics, Sunnyvale, CA, USA
Key Words:
(none)
Abstract:
The selectivity of Antrin® Injection (a motexafin lutetium sensitizer) with subsequent photoillumination by
732 nm far-red light was evaluated preclinically in several atherosclerosis models. Antrin was found to
selectively target diseased tissue in two experimental rabbit atheromatous plaque models; a
hypercholesterolemic diet model and a balloon injury model of restenosis using both systemic and
intra-arterial sensitizer delivery. Antrin was also found to localize in rodent models of graft coronary artery
disease and vein graft intimal hyperplasia. Subsequent illumination caused resolution in atherosclerosis
burden as well as a significant reduction in macrophage population.
PHOTOANGIOPLASTY: NEW APPLICATIONS OF PHOTODYNAMIC
THERAPY IN
ATHERSCLEROSIS
Authors:
S.G. Rockson
Institutions:
Stanford University, Stanford, USA
Key Words:
photoangioplasty, atherosclerosis, restenosis
Abstract:
Atherosclerosis has traditionally held appeal as a pathologic entity in which photodynamic therapy might
arrest or reverse the manifestations of disease. Earlier attempts to bring photodynamic therapy to the
human clinical arena in atherosclerosis were hampered by the limitations of photosensitizers under
investigation, including predisposition to phototoxic manifestations and light-induced trauma to surrounding,
normal vascular tissues. Many of these inherent limitations may be circumvented by newer photosensitizers
that are activated at longer, more optimal wavelengths of light energy. Advances in cateter design for the
endovascular delivery of light have also contributed to the greater applicability of photodynamic therapy in
human atherosclerosis. Initial experiences with one famiy of photosensitizers, the texaphyrins, indicate that
photodynamic therapy of human peripheral arterial atherosclerosis is feasible, safe, and well-tolerated.
Photodynamic therapy of atherosclerosis holds promise for the treatment of de novo atherosclerosis and
may have future applicability in the treatment, and perhaps prevention, of restenosis. |
